{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:53:29Z","timestamp":1791255209166,"version":"4.1.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cjca.2026.07.369","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:19:20Z","timestamp":1785194360000},"page":"2279-2281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glucagon-Like Peptide-1 Receptor Agonists and Aortic Stenosis: An Emerging Cardiometabolic Opportunity"],"prefix":"10.1016","volume":"42","author":[{"given":"Jacinthe","family":"Boulet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9999-111X","authenticated-orcid":false,"given":"Eileen","family":"O\u2019Meara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2026.07.369_bib1","first-page":"1857","article-title":"Canadian Cardiovascular Society\/Canadian Heart Failure Society 2025 guideline update for pharmacologic management of heart failure with nonreduced ejection fraction (LVEF > 40%)","volume":"41","author":"Virani","year":"2025","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2026.07.369_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2026.103046","article-title":"Excess and dysfunctional fat as a primary driver of heart failure with preserved ejection fraction: from institutional recognition to clinical integration","volume":"14","author":"Packer","year":"2026","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2026.07.369_bib3","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-24-0046","article-title":"GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms","volume":"263","author":"Mullur","year":"2024","journal-title":"J Endocrinol"},{"key":"10.1016\/j.cjca.2026.07.369_bib4","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.07.369_bib5","first-page":"1153","article-title":"2022 Canadian Cardiovascular Society guideline for use of GLP-1 receptor agonists and SGLT2 inhibitors for cardiorenal risk reduction in adults","volume":"38","author":"Mancini","year":"2022","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2026.07.369_bib6","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/ehf2.14560","article-title":"Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists","volume":"11","author":"Cimino","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cjca.2026.07.369_bib7","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1053\/j.gastro.2025.02.044","article-title":"Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis","volume":"169","author":"Younossi","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cjca.2026.07.369_bib8","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.07.369_bib9","first-page":"2299","article-title":"Cardiovascular outcomes with GLP-1 receptor agonists in patients with diabetes or obesity undergoing transcatheter aortic valve replacement","volume":"42","author":"Goyal","year":"2026","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2026.07.369_bib10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/ehjqcco\/qcaf135","article-title":"GLP-1 receptor agonists and clinical outcomes in patients with type 2 diabetes undergoing transcatheter aortic valve implantation","volume":"12","author":"Pham","year":"2026","journal-title":"Eur Heart J Qual Care Clin Outcomes"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X26010500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X26010500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:44:59Z","timestamp":1791254699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X26010500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0828282X26010500"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2026.07.369","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-Like Peptide-1 Receptor Agonists and Aortic Stenosis: An Emerging Cardiometabolic Opportunity","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2026.07.369","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2026.04.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}